<DOC>
<DOCNO>1050328_business_story_4542939.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Wockhardt to inject more funds into research kitty 

 Mumbai, March 27 (PTI): Banking on the new patent law, Wockhardt Ltd is increasing its research and development (R amp;D) spend to around Rs 125 crore in 2005-06.

 ?We are increasing our R amp;D spend and raise it to around 8.5-9 per cent of the total sales this year, banking on the new patent rules, which is expected to be beneficial for the country,? managing director Habil Khorakiwala said.

 The pharmaceuticals major would spend the amount for new drug discoveries, novel drug delivery system and reverse engineering processes, even as a specific portion would be earmarked for biotechnology and biopharmaceuticals, Khorakiwala said.

 In 2004-05, the company had spent around Rs 85 crore for R amp;D on a total sales of Rs 288 crore.

 The R amp;D would also include innovative process development for bulk actives using chemical, fermentation and peptide synthesis technologies, development of new medical nutrition products, clinical research including pharmacology, toxicology, pharmacokinetics, pharmacodynamics, agrochemicals and bio-agro products, he added.

 ?These multi-disciplinary and multi-technology R amp;D programmes will help Wockhardt gain a competitive advantage in the new patent regime,? Khorakiwala said.

 Wockhardt is aiming to provide new products in India and technology-based pharmaceutical bulk active and dosage forms in the American, European and other markets in the short-term.

 For the long-term, the companys research and development strategy is to discover new anti-infectives, antibiotics and anti-bacterials, he added. 




</TEXT>
</DOC>